Clinical Trial Update: Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a metabolically optimized, non-cytotoxic, low-dose weekly decitabine/venetoclax regimen in myelodysplastic syndromes, acute my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Dacogen (decitabine)
• Venclexta (venetoclax)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING | Results posted: 2025-08-26